| Pathology and Laboratory 2014 CPT Code Changes |
veenavardhini |
Dec 20, 2014 2:50:53 AM |
| Pathology and Laboratory 2014 CPT Code Changes |
yshi14 |
Dec 19, 2014 2:50:12 AM |
| Primary Antibody Selection & Optimization |
Qi Wang |
Dec 19, 2014 2:36:23 AM |
| [Niemz; Interview; 2014-10-31 10/31/14] |
wtamav14 |
Dec 19, 2014 2:19:49 AM |
| Frequently Asked Questions CMS 2014 Physician Fee Schedule Final Rule |
wtamav14 |
Dec 18, 2014 9:31:22 PM |
| Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment |
wtamav14 |
Dec 18, 2014 5:23:58 PM |
| Immunohistochemistry (IHC) Core: Fees |
wtamav14 |
Dec 18, 2014 5:19:19 PM |
| Detailed Guide |
yshi14 |
Dec 18, 2014 12:08:40 AM |
| Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors |
Qi Wang |
Dec 17, 2014 11:49:19 PM |
| Accurate and Economical Detection of ALK Positive Lung Adenocarcinoma with Semiquantitative Immunohistochemical Screening |
wtamav14 |
Dec 17, 2014 11:11:17 PM |
